Every article, presentation, spotlight, and news item we've tagged to Mental and Cognitive Health.
Showing 97–120 of 124
Urban environments in sub-Saharan Africa show accelerated inflammaging—chronic, low-grade systemic inflammation associated with aging—driven by environmental stressors including air pollution, pathogenic load, and dietary shifts. This research identifies modifiable environmental and lifestyle factors that influence the rate of immunological aging independent of chronological age.
Rafael Holdings secured exclusive MIT patent rights for cyclodextrin-based molecules targeting ApoE4-positive Alzheimer's disease by restoring cholesterol transport between brain cells. This represents a shift from amyloid-clearance paradigms toward addressing the cellular infrastructure that prevents pathological buildup in the first place.
Caregiving relationships that maintain shared physical activity and social engagement protect against isolation and functional decline in aging adults, with dementia-affected dyads showing particular vulnerability. The structure of caregiving partnerships—whether they preserve mutual participation or devolve into dependency—predicts health trajectories independent of diagnosis.
Aging in rats produces sex-dependent changes in emotional regulation, cognitive function, and brain immune cell populations, with females showing greater cognitive decline and males exhibiting more pronounced emotional dysregulation. These findings suggest that neuroinflammation and immune cell dynamics contribute to cognitive and emotional aging, with implications for understanding sex-specific vulnerabilities in human neurodegenerative conditions.
Somatostatin overexpression in neurons reduces microglial activation and inflammatory signaling while enhancing amyloid-β clearance in an Alzheimer's mouse model. Existing drugs targeting this pathway suggest translational potential for addressing neuroinflammation in cognitive decline.
Research published in PNAS Nexus proposes that autophagy dysfunction—a slowdown in cellular recycling—precedes amyloid and tau pathology in Alzheimer's disease. This upstream mechanism shifts the therapeutic target from clearing late-stage debris to restoring the cell's natural cleanup capacity earlier in disease progression.
Plasma protein structural changes—not just abundance—distinguish Alzheimer's disease progression and predict disease status independent of traditional genetic risk markers. This approach identifies conformational biomarkers that shift with disease stage, genotype, and sex, offering a measurable window into pathological mechanisms before cognitive decline becomes severe.
Nanoplastics have been detected in human brain tissue and show correlation with neurodegenerative disease severity and accelerated aging markers. The particles' ability to cross biological barriers and interact with pathological proteins suggests chronic, low-level exposure represents a longevity risk distinct from acute toxicity.
The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.
Blarcamesine demonstrated a measurable correlation between MRI-detected preservation of brain volume and slowing of cognitive decline in early Alzheimer's disease, with particularly strong outcomes in a genetically defined subpopulation. Long-term data suggest a potential delay in functional deterioration of approximately 18 months over 33 months of treatment.
Anavex presents evidence linking autism spectrum disorder and Alzheimer's disease through impaired autophagy and synaptic dysfunction, proposing that restoring cellular clearance pathways via their compound Blarcamesine may address both conditions. The finding connects neurodevelopmental and neurodegenerative disease through a shared cellular mechanism, with epidemiological data showing autistic adults face substantially elevated dementia risk.
Stroke in the context of chronic kidney disease triggers immune dysregulation that accelerates mitochondrial dysfunction and aging processes. This cascade reveals how organ system failure in one area can compromise cellular energy production and immunity simultaneously, with significant implications for longevity in populations with renal compromise.
Cognito Therapeutics and Ochsner Health are partnering to test Spectris, a non-invasive neuromodulation device that delivers synchronized light and sound stimulation to restore gamma oscillations disrupted in Alzheimer's disease. Early evidence shows the approach slows cognitive decline and reduces brain volume loss, with the collaboration designed to evaluate real-world clinical implementation across diverse healthcare settings.
Researchers developed a lipid nanoparticle that delivers mRNA encoding TRIM11, a natural ligase that disaggregates tau tangles, across the blood-brain barrier in mouse models of Alzheimer's disease. Treatment produced sustained cognitive and behavioral restoration comparable to wild-type mice, with reduction in tau pathology and neuroinflammatory markers.
Oral health functions as a systemic gateway affecting breathing mechanics, sleep quality, inflammation, and metabolism rather than existing as an isolated dental concern. Optimizing breathing patterns, airway function, and oral microbiota through evidence-based dental and postural interventions produces measurable improvements in cardiovascular health, sleep architecture, and immune function.
Physical exercise elevates circulating adiponectin, which activates PP2A phosphatase in the hippocampus to reduce pathological tau phosphorylation and restore cognitive function under chronic stress. This mechanism operates independently of adiponectin's other metabolic functions and identifies a direct molecular pathway by which exercise protects against Alzheimer's-like neuropathology.
Loneliness and depression/anxiety in older adults correlate with feeling older than one's chronological age, with longitudinal evidence suggesting emotional distress may accelerate subjective aging. This relationship has direct implications for how psychological states influence biological aging trajectories.
Overexpression of somatostatin, a neuropeptide normally produced by neurons, reduces microglial activation and amyloid-β burden while improving cognitive function in an Alzheimer's disease mouse model. The finding identifies a previously untested communication pathway between neurons and immune cells that becomes dysregulated in the disease and offers a target for existing pharmaceuticals.
Age-related cognitive decline involves microbiome remodeling, with Parabacteroides goldsteinii identified as a primary driver that suppresses neuronal activation in the hippocampus via the vagus nerve. Antibiotic treatment reverses the cognitive deficit even after it develops, establishing the microbiome as a modifiable mechanism rather than an irreversible consequence of aging.
Obicetrapib, a CETP inhibitor, demonstrates cardiovascular benefits and potential neuroprotective effects against Alzheimer's disease—outcomes that distinguish it from four previous compounds in this drug class. The mechanism addresses both systemic lipid metabolism and cerebral amyloid pathology, making it relevant to multi-system longevity strategies.
A 15-year Swedish cohort study found that unprocessed meat consumption was associated with preserved cognitive trajectory and reduced dementia risk in APOE ε4 carriers, effectively neutralizing the genotype's established cognitive penalty at higher intake levels. This finding challenges the assumption that ε4 carriers universally benefit from plant-forward diets and suggests ancestral dietary patterns may interact with genetic risk architecture in ways that modern nutritional guidelines do not account for.
Roche has obtained CE mark approval for a blood test that identifies ApoE4 carriers, a genetic variant associated with increased Alzheimer's risk. This test streamlines risk stratification and treatment planning by enabling clinicians to prioritize patients for further evaluation and guide therapeutic decisions, particularly regarding amyloid-targeting therapies that carry differential risk profiles based on ApoE4 status.
Cognito Therapeutics and Ochsner Health have established a regional platform to evaluate Spectris, a non-invasive device that uses synchronized light and sound to stimulate gamma-frequency brain activity, alongside clinical infrastructure to assess its effectiveness in cognitive decline and Alzheimer's disease. The collaboratory will generate real-world data on treatment response, cost-effectiveness, and scalability across diverse populations.
Somatic mutations accumulating in microglia—brain immune cells—correlate with Alzheimer's disease pathology and cognitive decline. These acquired genetic variants, distinct from inherited risk factors, represent a previously underappreciated mechanism driving neurodegeneration and suggest new intervention points before symptomatic disease emerges.
